Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK’s NICE Goes Ahead With Parkinson’s Product Funding But Pending Real-World Data

Executive Summary

Five remote monitoring medical devices that have “transformational” potential for Parkinson’s disease are to be conditionally funded via the UK’s National Health Service in a drive to address clinical and cost-effectiveness uncertainties using data from real patients.

You may also be interested in...



UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes

The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed changes to the branded medicines statutory pricing scheme could be grounds for legal challenge.

EU Needs Better Data Tools To Combat Vaccine-Preventable Cancers, Says Industry

Data on vaccine coverage rates and trends in vaccine-preventable disease incidence in the EU are crucial but are often not available or inaccurate, according to EFPIA subgroup Vaccines Europe.

Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA

Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel